Researchers at the George Washington University School of Medicine and Health Sciences, in partnership with Baylor College of Medicine, announced on Mar. 18 that a phase 2 clinical trial of a candidate hookworm vaccine produced encouraging results in protecting against infection.
Hookworm is one of the most common parasitic diseases worldwide and is a major cause of iron-deficiency anemia, especially among children and pregnant women in low-resource areas. There is currently no licensed vaccine for this disease, making the development of an effective preventive measure significant for global health.
The findings were published in The Lancet Infectious Diseases. The study showed that healthy adult volunteers who received three doses of one formulation—containing Na-GST-1 protein combined with an adjuvant called CpG—had much lower levels of infection after controlled exposure to the parasite compared to those who received placebo. “An effective hookworm vaccine could become an essential tool to prevent anemia and improve health outcomes in vulnerable populations,” said Dr. David Diemert, lead researcher and professor at George Washington University School of Medicine & Health Sciences. “These findings represent an important step toward that goal.”
Nearly 113 million people are estimated to be infected by hookworm globally; some estimates place this number over 400 million, according to data presented by researchers. Dr. Peter Hotez, dean at Baylor College of Medicine’s National School of Tropical Medicine and co-director at Texas Children’s Hospital Center for Vaccine Development, said: “Almost 40 percent of children under five years of age struggle with anemia, and an effective hookworm vaccine could give many of them the opportunity to live a healthy, productive life.”
The study included participants from Washington D.C., all adults who had previously undergone safety testing for these vaccines during earlier trials conducted not only in the United States but also Brazil and Gabon. Participants receiving the Na-GST-1/Al–CpG formulation had median egg counts drop to zero compared with a median count above sixty-six eggs per gram among those given placebo.
Dr. Maria Elena Bottazzi from Baylor College added: “A combination vaccine could pack a particularly powerful punch because in areas with high rates of both malaria and hookworm, it’s not always clear which one is the primary cause of anemia.”
Baylor College contributes to community service as part its core mission according to its official website. It operates independently while engaging in clinical partnerships according to its official website and focuses on advancing research, education, patient care, as well as community service as stated by its official website. Paul Klotman holds roles as president, chief executive officer, and executive dean at Baylor College according to its official website. The college collaborates within integrated health sciences environments as reported by its official site, providing education across schools while advancing biomedical research through partnerships according to information provided online.
Based on these results from phase 2 trials funded by the National Institute of Allergy and Infectious Diseases (NIAID), researchers plan further clinical evaluation for this promising candidate either alone or potentially combined with other vaccines.
